Cytokinetic effects of Wee1 disruption in pancreatic cancer.

about

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.

P2860

Q55445065-5B60911B-A5D9-4887-900E-8C2D5202FDD2 Q55478403-39AEC98E-8925-460B-A10E-58D2DFF2563F

P2860

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

Item

http://www.wikidata.org/entity/Q38793178

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

@en

type

Item

label

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

@en

prefLabel

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

@en

P1476

Cytokinetic effects of Wee1 disruption in pancreatic cancer

@en

P2093

Megha Chandrashekhar

http://www.w3.org/2001/XMLSchema#string

Qing Chang

http://www.w3.org/2001/XMLSchema#string

Troy Ketela

http://www.w3.org/2001/XMLSchema#string

Yaroslav Fedyshyn

http://www.w3.org/2001/XMLSchema#string

P2860

Improving the efficacy of chemoradiation with targeted agents

A third-generation lentivirus vector with a conditional packaging system

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase.

Pooled lentiviral shRNA screening for functional genomics in mammalian cells.

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Feedback regulation of opposing enzymes generates robust, all-or-none bistable responses.

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.

The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

P304

593-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15384101.2016.1138188

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Hedley

Jason Moffat

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26890070

http://www.w3.org/2001/XMLSchema#string

P932

5056606

http://www.w3.org/2001/XMLSchema#string

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

about

P2860

P2860

Cytokinetic effects of Wee1 disruption in pancreatic cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932